OS Therapies (NYSEAMERICAN:OSTX) Releases Earnings Results

OS Therapies (NYSEAMERICAN:OSTX) posted its earnings results on Monday. The company reported ($0.27) EPS for the quarter, FiscalAI reports.

OS Therapies Price Performance

Shares of NYSEAMERICAN:OSTX opened at $1.73 on Tuesday. The stock has a market cap of $68.39 million, a P/E ratio of -1.75 and a beta of -1.34. The firm has a fifty day moving average price of $1.52 and a 200 day moving average price of $1.55. OS Therapies has a 1-year low of $1.15 and a 1-year high of $2.57.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on OSTX shares. Zacks Research cut shares of OS Therapies from a “hold” rating to a “strong sell” rating in a research note on Wednesday, May 6th. D. Boral Capital reiterated a “buy” rating and set a $20.00 price target on shares of OS Therapies in a research note on Thursday, April 30th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, OS Therapies presently has an average rating of “Hold” and an average price target of $18.50.

Institutional Trading of OS Therapies

Hedge funds have recently made changes to their positions in the company. Susquehanna International Group LLP acquired a new stake in shares of OS Therapies in the 3rd quarter worth $29,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of OS Therapies in the 3rd quarter worth $40,000. Ground Swell Capital LLC acquired a new stake in shares of OS Therapies in the 3rd quarter worth $40,000. Bridgeway Capital Management LLC acquired a new stake in shares of OS Therapies in the 2nd quarter worth $47,000. Finally, Jane Street Group LLC acquired a new stake in shares of OS Therapies in the 4th quarter worth $39,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.